Zentalis Pharmaceuticals (ZNTL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.13, -4.91% vs the prior close of $2.24.
- Volume 1.10M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ZNTL slides 4.9% to $2.13, a 6-month low, 5 down days in a row. Closed at $2.13, -4.91% vs the prior close of $2.24. Day range $2.10–$2.28, opened at $2.25.
ZNTL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ZNTL slides 4.9% to $2.13, a 6-month low, 5 down days in a row
- Closed at $2.13, -4.91% vs the prior close of $2.24. Day range $2.10–$2.28, opened at $2.25.
- Volume was 1.10M shares, 0.9x its 50-day average of 1.19M.
- Price is -35.5% vs its 50-day average ($3.30) and -38.7% vs its 200-day average ($3.47).
- 52-week range $1.21–$6.95; today's close sits at 16% of that range, 69.4% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — ZNTL slides 3.4% to $2.24, a 6-month low, 4 down days in a row
- Closed at $2.24, -3.45% vs the prior close of $2.32. Day range $2.21–$2.40, opened at $2.27.
- Volume was 2.03M shares, 1.8x its 50-day average of 1.16M.
- Price is -33.3% vs its 50-day average ($3.36) and -35.4% vs its 200-day average ($3.47).
- 52-week range $1.21–$6.95; today's close sits at 18% of that range, 67.8% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — ZNTL slides 3.3% to $2.32, a 6-month low, 3 down days in a row
- Closed at $2.32, -3.33% vs the prior close of $2.40. Day range $2.30–$2.45, opened at $2.44.
- Volume was 865.30K shares, 0.7x its 50-day average of 1.16M.
- Price is -32.1% vs its 50-day average ($3.41) and -33.0% vs its 200-day average ($3.46).
- 52-week range $1.21–$6.95; today's close sits at 19% of that range, 66.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ZNTL slides 4.8% to $2.40, a 6-month low
- Closed at $2.40, -4.76% vs the prior close of $2.52. Day range $2.39–$2.54, opened at $2.53.
- Volume was 570.10K shares, 0.5x its 50-day average of 1.16M — lighter than usual.
- Price is -30.8% vs its 50-day average ($3.47) and -30.6% vs its 200-day average ($3.46).
- 52-week range $1.21–$6.95; today's close sits at 21% of that range, 65.5% below the 52-week high.
Oct 12, 2026 — ZNTL slides 4.5% to $2.52
- Closed at $2.52, -4.55% vs the prior close of $2.64. Day range $2.51–$2.64, opened at $2.64.
- Volume was 546.10K shares, 0.5x its 50-day average of 1.17M — lighter than usual.
- Price is -28.2% vs its 50-day average ($3.51) and -27.0% vs its 200-day average ($3.45).
- 52-week range $1.21–$6.95; today's close sits at 23% of that range, 63.7% below the 52-week high.
Oct 9, 2026 — ZNTL jumps 5.2% to $2.64
- Closed at $2.64, +5.18% vs the prior close of $2.51. Day range $2.51–$2.66, opened at $2.56.
- Volume was 612.40K shares, 0.5x its 50-day average of 1.18M — lighter than usual.
- Price is -25.7% vs its 50-day average ($3.56) and -23.4% vs its 200-day average ($3.45).
- 52-week range $1.21–$6.95; today's close sits at 25% of that range, 62.0% below the 52-week high.
Oct 8, 2026 — ZNTL dips 1.6% to $2.51, a 6-month low, 3 down days in a row
- Closed at $2.51, -1.57% vs the prior close of $2.55. Day range $2.39–$2.54, opened at $2.51.
- Volume was 1.27M shares, 1.1x its 50-day average of 1.17M.
- Price is -30.3% vs its 50-day average ($3.60) and -27.1% vs its 200-day average ($3.44).
- 52-week range $1.21–$6.95; today's close sits at 23% of that range, 63.9% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ZNTL slides 4.5% to $2.55
- Closed at $2.55, -4.49% vs the prior close of $2.67. Day range $2.54–$2.68, opened at $2.63.
- Volume was 820.10K shares, 0.7x its 50-day average of 1.17M.
- Price is -30.0% vs its 50-day average ($3.64) and -25.8% vs its 200-day average ($3.44).
- 52-week range $1.21–$6.95; today's close sits at 23% of that range, 63.3% below the 52-week high.
Oct 6, 2026 — ZNTL slides 4.0% to $2.67
- Closed at $2.67, -3.96% vs the prior close of $2.78. Day range $2.65–$2.82, opened at $2.81.
- Volume was 827.60K shares, 0.7x its 50-day average of 1.18M.
- Price is -27.6% vs its 50-day average ($3.69) and -22.2% vs its 200-day average ($3.43).
- 52-week range $1.21–$6.95; today's close sits at 25% of that range, 61.6% below the 52-week high.
Oct 5, 2026 — ZNTL jumps 10.3% to $2.78 on 2.6x normal volume
- Closed at $2.78, +10.32% vs the prior close of $2.52. Day range $2.63–$2.84, opened at $2.69.
- Volume was 2.99M shares, 2.6x its 50-day average of 1.14M — unusually heavy trading.
- Price is -25.3% vs its 50-day average ($3.72) and -18.8% vs its 200-day average ($3.42).
- 52-week range $1.21–$6.95; today's close sits at 27% of that range, 60.0% below the 52-week high.
Oct 2, 2026 — ZNTL slides 3.3% to $2.52, a 6-month low
- Closed at $2.52, -3.26% vs the prior close of $2.61. Day range $2.49–$2.65, opened at $2.64.
- Volume was 1.45M shares, 1.3x its 50-day average of 1.13M.
- Price is -32.9% vs its 50-day average ($3.75) and -26.2% vs its 200-day average ($3.42).
- 52-week range $1.21–$6.95; today's close sits at 23% of that range, 63.7% below the 52-week high.
ZNTL latest news & SEC filings
Every SEC filing by or about ZNTL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bruns Ingmar received an award of 9,727 shares at $2.18 (≈$21.20K) on Sep 30, 2026; now holds 43,059
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 19, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Walters William Thurman bought 4,335,000 shares at $3.50 (≈$15.17M) on Aug 14, 2026
- Walters William Thurman bought 4,335,000 shares at $3.50 (≈$15.17M) on Aug 14, 2026
- Walters Group bought 4,335,000 shares at $3.50 (≈$15.17M) on Aug 14, 2026
- Walters Group bought 4,335,000 shares at $3.50 (≈$15.17M) on Aug 14, 2026
- Walters Susan Berkley bought 4,335,000 shares at $3.50 (≈$15.17M) on Aug 14, 2026
- Walters Susan Berkley bought 4,335,000 shares at $3.50 (≈$15.17M) on Aug 14, 2026
- …plus 6 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$42.29M (prior year -$26.87M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.59 (prior year -$0.37) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ZNTL
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 26, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.15% (largest 10.3%). That is a volatile stock.
- Liquidity: about 1.37M shares (≈$2.92M) trade per day on average.
- 52-week position: $2.13 vs a range of $1.21–$6.95 (16% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 12 open-market buys, 13 sales; latest: William Thurman Walters bought 4,335,000 shares on Aug 14, 2026.
- Latest filings: 8-K Aug 14, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 71.67M shares outstanding (Aug 3, 2026), -0.6% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ZNTL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.25 | 2.28 | 2.10 | 2.13 | 1.10M |
| Oct 15, 2026 | 2.27 | 2.40 | 2.21 | 2.24 | 2.03M |
| Oct 14, 2026 | 2.44 | 2.45 | 2.30 | 2.32 | 865.30K |
| Oct 13, 2026 | 2.53 | 2.54 | 2.39 | 2.40 | 570.10K |
| Oct 12, 2026 | 2.64 | 2.64 | 2.51 | 2.52 | 546.10K |
| Oct 9, 2026 | 2.56 | 2.66 | 2.51 | 2.64 | 612.40K |
| Oct 8, 2026 | 2.51 | 2.54 | 2.39 | 2.51 | 1.27M |
| Oct 7, 2026 | 2.63 | 2.68 | 2.54 | 2.55 | 820.10K |
| Oct 6, 2026 | 2.81 | 2.82 | 2.65 | 2.67 | 827.60K |
| Oct 5, 2026 | 2.69 | 2.84 | 2.63 | 2.78 | 2.99M |
| Oct 2, 2026 | 2.64 | 2.65 | 2.49 | 2.52 | 1.45M |
| Oct 1, 2026 | 2.74 | 2.78 | 2.58 | 2.61 | 1.90M |
| Sep 30, 2026 | 2.71 | 2.80 | 2.61 | 2.77 | 1.01M |
| Sep 29, 2026 | 2.62 | 2.81 | 2.57 | 2.71 | 4.78M |
| Sep 28, 2026 | 2.70 | 2.70 | 2.57 | 2.60 | 1.27M |
| Sep 25, 2026 | 2.75 | 2.77 | 2.65 | 2.70 | 1.07M |
| Sep 24, 2026 | 2.84 | 2.89 | 2.73 | 2.75 | 1.17M |
| Sep 23, 2026 | 3.07 | 3.09 | 2.78 | 2.87 | 1.45M |
| Sep 22, 2026 | 3.07 | 3.14 | 3.01 | 3.08 | 956.30K |
| Sep 21, 2026 | 3.15 | 3.15 | 2.99 | 3.03 | 675.30K |
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals (ZNTL) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. Fiscal year ends December 31. SEC CIK 1725160.
ZNTL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Shannon Campbell | Director | May 27, 2026 |
| Julia Marie Eastland | CEO & President | Feb 10, 2026 |
| David Michael Johnson | Director | Jun 18, 2026 |
| Enoch Kariuki | Director | Jun 18, 2026 |
| Scott Dunseth Myers | Director | Jun 18, 2026 |
| Jan Skvarka | Director | Jun 18, 2026 |
| Luke Nathaniel Walker | Director | Jun 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ingmar Bruns | Chief Medical Officer | Feb 10, 2026 |
| James B Bucher | Chief Legal Officer | Jan 9, 2026 |
| Julia Marie Eastland | CEO & President | Feb 10, 2026 |
| Vincent Vultaggio | PAO and PFO | Feb 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | William Thurman Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | William Thurman Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | Group Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | Group Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | Susan Berkley Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | Susan Berkley Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | William Thurman Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | William Thurman Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | Group Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | Group Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | Susan Berkley Walters | Buy | 4,335,000 | $3.50 |
| Aug 14, 2026 | Susan Berkley Walters | Buy | 4,335,000 | $3.50 |
| Feb 10, 2026 | Vincent Vultaggio | Sale | 6,894 | $2.42 |
| Feb 10, 2026 | Vincent Vultaggio | Sale | 6,894 | $2.42 |
| Feb 10, 2026 | Vincent Vultaggio | Sale | 6,894 | $2.42 |
ZNTL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-137.06M | -1.91 | $-125.25M |
| Dec 31, 2024 | $67.42M | $-165.84M | -2.33 | $-170.86M |
| Dec 31, 2023 | $0 | $-292.19M | -4.47 | $-207.82M |
| Dec 31, 2022 | $0 | $-236.81M | -4.48 | $-163.75M |
| Dec 31, 2021 | — | $-158.72M | -3.72 | $-154.09M |
Latest balance sheet: total assets $215.33M, total liabilities $71.68M, cash $24.78M (as of Jun 30, 2026).
ZNTL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $5.00 |
| May 12, 2026 | 8-K Item 2.02 (results) | $4.28 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $2.67 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $1.32 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $1.38 |
| May 14, 2025 | 8-K Item 2.02 (results) | $1.19 |
| Mar 26, 2025 | 8-K Item 2.02 (results) | $1.76 |
| Aug 9, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 6, 2023 | 8-K Item 2.02 (results) | — |
| Aug 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ZNTL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.